National Cancer Centre Singapore (NCCS), Singapore Clinical Research
Institute (SCRI) and IMS Health (NYSE:IMS) will collaborate to develop
its first Liver Cancer or Hepatocellular Carcinoma (HCC) Registry in
Asia through the Asian HCC Physician Network.
The non-identified data from this Registry can help policymakers and
health care professionals formulate strategies to manage liver cancer
This collaboration is led by Prof. Pierce Chow, Senior Consultant
Surgeon at NCCS and Chairman of the Physician Network.
“HCC is a leading cause of cancer-related death worldwide, and the
burden of this devastating cancer is expected to increase further in
coming years. The collection and analysis of epidemiologic HCC data will
play a critical role in guiding future disease prevention strategies and
optimizing patient management,” said Associate Prof. Teoh Yee Leong,
Public Health Physician and CEO of Singapore Clinical Research Institute.
Previous epidemiologic studies have highlighted striking global
variations in the incidence of HCC, which is particularly high in much
of East Asia and sub-Saharan Africa, and lower, but on the rise in North
America and most of Europe. Although previous studies have contributed
considerably to the knowledge of HCC epidemiology, there are limitations
associated with the currently available data. This arose from studies
performed at different times in the past, using varying methodologies,
and with diverse patient populations.
“This information gap prevents estimation of current and future disease
burden and impedes efforts to lobby health policymakers to improve
public health measures, as given the size of Asia Pacific populations,
prevention rather than treatment of non-communicable diseases remains
key,” added Prof. Teoh.
NCCS Director Prof. Soo Khee Chee said, “This public-private registry is
timely and leverages on the Asia-Pacific HCC network that we have
developed over the last two decades. The aim of the registry is aligned
with the mission of NCCS and we look forward to better prevention and
treatment strategies for HCC in Asia Pacific.”
NCCS Prof. Pierce Chow said a fresh approach to the study of the
epidemiology of HCC is required if HCC disease prevention and treatment
strategies are to be adequately directed and supported in coming years.
”Real world data on the presentation, clinical trajectory and management
of HCC in the Asia-Pacific must be prospectively collected on the ground
if we were to improve public health measures and develop effective
public health strategies,” explained Prof. Chow.
According to the Vice President IMS Health Asia Pte Ltd., Mr. Amit
Backliwal, "Cancer in Asia is fast becoming a huge burden of disease and
cost of care is now spiraling. With access to non-identified,
longitudinal patient data, IMS will be able to help healthcare
stakeholders in more informed decision making and drive better health
outcomes overall through proprietary analytics and technology solutions."
This public-private collaboration will also provide invaluable
information to the pharmaceutical industry, governmental and insurance
payers and physicians, delivering a complete longitudinal picture of the
disease using a combination of retrospective and prospective clinical,
associated health costs and patient reported outcomes data. The Registry
will help to answer important questions such as different treatment
patterns / strategies; health care resource use and costs of treatments;
as well as first-hand insights to patients’ perspectives on their
Using this real world data, government planning agencies and
pharmaceutical companies can benefit through bespoke analytics to
establish their clinical development and product strategies. Payers will
have a good understanding of the disease burden and budget impact to
better craft the public health policies. Physicians will be able to use
this data to better optimize care pathways enhancing treatment outcomes
for HCC patients.
About National Cancer Centre Singapore
National Cancer Centre Singapore (NCCS) provides a holistic and
multi-disciplinary approach to cancer treatment and patient care. We
treat almost 70 per cent of the public sector oncology cases, and they
are benefiting from the sub-specialization of our clinical oncologists.
NCCS is also accredited by the US-based Joint Commission International
for its quality patient care and safety.
To deliver among the best in cancer treatment and care, our clinicians
work closely with our scientists who conduct robust cutting-edge
clinical and translational research programs which are internationally
recognized. NCCS strives to be a global leading cancer centre, and
shares its expertise and knowledge by offering training to local and
overseas medical professionals. www.nccs.com.sg
About Singapore Clinical Research Institute
Singapore Clinical Research Institute (SCRI) is a National Academic
Research Organization dedicated to enhance the standards of human
clinical research. Its mission is to spearhead and develop core
capabilities, infrastructure and scientific leadership for clinical
research in Singapore. SCRI is a national clinical trials coordination
centre that works with National Medical Research Council (NMRC) to
assist the Ministry of Health in implementing clinical trials policy and
strategic initiatives to support and develop clinical research
In driving towards its vision, SCRI collaborates with clinicians to
enhance Singapore’s clinical research and strengthen its expertise in
executing multi-site, multi-national studies and the development of
regional clinical research networks.
SCRI is a wholly-owned subsidiary of MOH Holdings. http://www.scri.edu.sg
About IMS Health
IMS Health is a leading global information and technology services
company providing clients in the healthcare industry with end-to-end
solutions to measure and improve their performance. Our 7,500 services
experts connect configurable SaaS applications to 10+ petabytes of
complex healthcare data in the IMS One™ cloud platform, delivering
unique insights into diseases, treatments, costs and outcomes. The
company’s 15,000 employees blend global consistency and local market
knowledge across 100 countries to help clients run their operations more
efficiently. Customers include pharmaceutical, consumer health and
medical device manufacturers and distributors, providers, payers,
government agencies, policymakers, researchers and the financial
As a global leader in protecting individual patient privacy, IMS Health
uses anonymous healthcare data to deliver critical, real-world disease
and treatment insights. These insights help biotech and pharmaceutical
companies, medical researchers, government agencies, payers and other
healthcare stakeholders to identify unmet treatment needs and understand
the effectiveness and value of pharmaceutical products in improving
overall health outcomes. Additional information is available at www.imshealth.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160201006385/en/